Radiotherapy to the prostate alongside standard treatment can keep some men with advanced prostate cancer alive for longer without detriment to quality of life, long-term study results confirm.

Adding abiraterone to the standard treatment for locally advanced prostate cancer, where the cancer has a high chance of spreading*, could halve the risk of death from the disease.

Giving the drug abiraterone alongside standard hormone therapy helps men with high-risk prostate cancer, that has not spread elsewhere in the body, live longer.